AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06259422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 125I-iothalamate and 131I-hippuran
Description: Subjects will receive 125I-iothalamate and 131I-hippuran as part of their routine clinical care.
Study NCT05547425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blur Obfuscation
Description: Blurring is applied to objects and people in the background of images.
Study NCT05547425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edge Obfuscation
Description: Objects and people in the background of images are replaced with an outline of the object.
Study NCT05547425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartoon Obfuscation
Description: Blurring is applied to objects and people in the background of images and the wearer's face is concealed with cartoon faces.
Study NCT05547425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raw images
Description: No editing is performed on images.
Study NCT05414539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OptiCogs Online
Description: A multicomponent intervention to rehabilitate cognitive deficits in people post-stroke
Study NCT05873543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smartphone-assisted hybrid cardiac rehabilitation (SHCR)
Description: The 12-week case manager-led SHCR program includes:~* Customized exercise prescriptions following ACSM's heart failure guidelines.~* A hybrid program combining in-person sessions, home self-exercise, and videoconferencing for exercise coaching(optional), supported by a smartphone app.~* Case managers instruct patients on a communication app for weekly follow-ups, health education messages, exercise reminders, and progress tracking, including metrics like blood pressure, heart rate, weight, and symptoms.
Study NCT04807985 — intervention group
Intervention type: DEVICE
Intervention: JVPHome and ultrasound
Description: Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
Study NCT05803018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion
Study NCT05688930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENMT (Experimental Group)
Description: The neuromuscular injury prevention intervention protocol contains field work activities that involve proprioceptive exercises, flexibility, and specific and general muscle strength of the MMII and trunk soccer players.
Study NCT05688930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIFA 11+ (Control Group)
Description: Treatment or experimental condition. 1: FIFA 11+ Program
Study NCT05494684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensoral Nature-based Intervention
Description: The intervention includes a multi-sensory nature experience using natural materials and a virtually created natural environment.
Study NCT06189144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emollient cream treatment
Description: Rilastil Difesa Sterile cream
Study NCT06189144 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no treatment
Description: no treatment
Study NCT05236738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Specified dose on specified days
Study NCT05236738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Specified dose on specified days
Study NCT05236738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Cobicistat Mini-tablet
Description: Specified dose on specified days
Study NCT06257927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuko Pamoja
Description: Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context.
Study NCT05334342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-GI Diet
Description: Participants will be given a low glycemic index diet
Study NCT05334342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-GI Diet
Description: Participants will be given a high glycemic index diet
Study NCT06649968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DESC-Glove (active)
Description: Rehabilitation treatment for the upper limb using the DESC-Glove device. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20-minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. During each session, patients will wear the DESC-Glove on the affected hand, receiving vibratory stimuli that are synchronized with the exercises being performed.
Study NCT06649968 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DESC-Glove (sham)
Description: Rehabilitation treatment for the upper limb using the DESC-Glove device. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20-minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. During each session, patients will wear the DESC-Glove on the affected hand, but will not receive any vibratory stimuli.
Study NCT06649968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rehabilitation
Description: Traditional rehabilitation treatment for the upper limb. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20- minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. The DESC- Glove will not be used during this treatment.
Study NCT06651112 — intervention group
Intervention type: DRUG
Intervention: Antipsychotic drugs
Description: Any Antipsychotic drugs prescripbe as standrd of care for this specific populaton
Study NCT05535075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vancomycin model-informed precision dosing
Description: A dosing calculator is used for a posteriori calculation of vancomycin dose using a target AUC/MIC between 400-600 mg\*h/L
Study NCT05535075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin treatment
Study NCT05535075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin treatment
Study NCT04969237 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamine D in blood samples
Description: vitamine D values
Study NCT06086145 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06310551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral VH4524184
Description: VH4524184 to be taken orally.
Study NCT05782725 — intervention group
Intervention type: OTHER
Intervention: Comparison of laboratory test results in women in the 4 study arms
Description: Comparison of AMH, FSH, LH, estradiol, AFC/ ovarian volume on ultrasound in women in the 4 study arms
Study NCT05088369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM201
Description: HM201 will be administered intravenously.
Study NCT05088369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously.
Study NCT05797831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
Study NCT05797831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Navtemadlin Placebo
Description: Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
Study NCT06178861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group wearing a radiotherapy bra
Description: Group wearing a radiotherapy bra
Study NCT06171269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation to the prostate gland will be given daily (Mon-Friday) for 4 weeks.
Study NCT06171269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: The study doctor will use an MRI scan to take pictures of the prostate gland. These images of the prostate gland will let the study doctor know which areas of the prostate contain cancer cells that need to be targeted with higher doses of radiation and which uninvolved areas to target with lower doses of radiation.
Study NCT06171269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Treatment of treating physician choice will be given for 6-24 months.
Study NCT06637631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT06637631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAR441566 matching Placebo
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT06555328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSU lower dose treatment
Description: CSU lower dose treatment
Study NCT06555328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSU high dose treatment
Description: CSU high dose treatment
Study NCT06555328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSU non responders IgE - high dose treatment
Description: CSU non responders IgE - high dose treatment
Study NCT06555328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS low dose treatment
Description: HS low dose treatment
Study NCT06555328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS medium dose treatment
Description: HS medium dose treatment
Study NCT06555328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS high dose treatment
Description: HS high dose treatment
Study NCT04757194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: openTriage - Alitis algorithm
Description: A machine learning algorithm (Gradient boosting) applied to structured data collected in the Alitis Clinical Decision Support system, patient demographics, and free-text notes.
Study NCT06372145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Pharmaceutical form:Tablet-Route of administration:oral
Study NCT06372145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Tablet-Route of administration:oral
Study NCT06372145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Tablet-Route of administration:oral
Study NCT06372145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: Pharmaceutical form:Tablet-Route of administration:oral
Study NCT05010772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study NCT05010772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO
Study NCT05010772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given PO
Study NCT05010772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO
Study NCT05010772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04495959 — intervention group
Intervention type: DRUG
Intervention: 68Ga-HTK03149
Description: PET/MRI scan with radiotracer 68Ga-HTK03149
Study NCT03538236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intragastric balloon
Description: Intragastric balloon insertion will be performed by an endoscopist under monitored anesthesia care. The Intragastric BalIoon (GB) comes as a deflated balloon pre-loaded on a catheter, which is inserted transorally into the proximal gastric body. An endoscope is then inserted alongside the device allowing for direct visualization of the balloon. Once in place, the intragastric balloon will be filled with saline through an external port. The balloon is inserted for 6 months then retrieved endoscopically
Study NCT03538236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: All patients included in the study will undergo an evaluation by a nutritionist. All participants will receive recommendations for a diet. Participants will be instructed to keep a daily food diary and will meet with the nutritionist to reinforce the behavior every 12 weeks for 12 months.
Study NCT03538236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: All patients included in the study will undergo an evaluation by a nutritionist. All participants will receive recommendations for a diet. Participants will be instructed to keep a daily food diary and will meet with the nutritionist to reinforce the behavior every 12 weeks for 12 months.
Study NCT06310551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation A SC
Description: Low (\<1mL) starting dose of VH4524184 LAI Formulation A administered subcutaneously.
Study NCT06310551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation A SC
Description: Starting dose of Placebo Formulation A administered subcutaneously.
Study NCT06012708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN510 60mg/day + KN713 60mg/day
Description: Once daily with 28 days (4 weeks) as one cycle.
Study NCT06012708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN510 120mg/day + KN713 60mg/day
Description: Once daily with 28 days (4 weeks) as one cycle.
Study NCT06012708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN510 120mg/day + KN713 90mg/day
Description: Once daily with 28 days (4 weeks) as one cycle.
Study NCT06012708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN510 120mg/day + KN713 120mg/day
Description: Once daily with 28 days (4 weeks) as one cycle.
Study NCT03799991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular physical therapy
Description: Vestibular therapy is a set of exercises delivered by a physical therapist involving head movements. The therapy is delivered over a course of 8 weeks.
Study NCT06310551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Dose of rHuPH20 administered subcutaneously.
Study NCT03799991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Strength and flexibility exercises that do not involve head movements.
Study NCT06310551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation B SC
Description: Starting dose of VH4524184 LAI Formulation B administered subcutaneously.
Study NCT06310551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation B SC
Description: Starting dose of Placebo Formulation B administered subcutaneously.
Study NCT06310551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation C SC
Description: Starting dose of VH4524184 LAI Formulation C administered subcutaneously.
Study NCT03929952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback treatment
Description: 20 sessions of neurofeedback of 5 minutes each consisting of :~* The patient is equipped with an electroencephalography headset. The feedback visual has the form of a candle flame and is modulated by alpha synchrony.~* The height of the flame is proportional to the intensity of the patient's pain. The patient has to concentrate on the height of this flame by thought to modulate it and, at the same time, to decrease the intensity of his own pain.
Study NCT03929952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging (fMRI) scans
Description: The patient in alpha synchrony related state and in rating state will undergo an fMRI
Study NCT06065540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of cagrilintide is reached.
Study NCT06065540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide
Description: Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of cagrilintide is reached.
Study NCT06065540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of semaglutide is reached.
Study NCT06310551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation C SC
Description: Dose of Placebo Formulation C administered subcutaneously.
Study NCT06065540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of semaglutide is reached.
Study NCT06310551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation A IM
Description: Starting dose VH4524184 LAI Formulation A administered intramuscularly.
Study NCT06065540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cagrilintide
Description: Participants will receive placebo matched to cagrilintide subcutaneously.
Study NCT06065540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo semaglutide
Description: Participants will receive placebo matched to semaglutide subcutaneously.
Study NCT06310551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation A IM
Description: Dose of Placebo Formulation A administered intramuscularly.
Study NCT06310551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184 Formulation B IM
Description: Starting dose VH4524184 LAI Formulation B administered intramuscularly.
Study NCT06310551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Formulation B IM
Description: Dose of Placebo Formulation B administered intramuscularly.
Study NCT04950270 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood copeptin monitoring
Description: Blood copeptin monitoring during the first 6 days of ICU stay with PRES
Study NCT04950270 — intervention group
Intervention type: OTHER
Intervention: phone interview
Description: Structured phone interview at 3 months to collect vital status and modified Rankin Scale score
Study NCT05905653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1012600 ophthalmic solution 0.002%
Description: 1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days
Study NCT05055297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SELUTION SLR™ DEB 014
Description: a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
Study NCT05055297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain (Uncoated) Balloon Angioplasty (PTA)
Description: a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
Study NCT05093634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Subcutaneous Injection
Study NCT05093634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection
Study NCT04719273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Onapristone
Description: Given PO
Study NCT05303922 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual-energy CT
Description: Dual-energy CT
Study NCT05303922 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI
Study NCT05119322 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GlutenDetect home urine test
Description: GFD compliance self-asessment using a home rapid test for GIP detection in urine.
Study NCT02446210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim 200
Description: Transcranial Magnetic Stimulation
Study NCT02446210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digitimer electrical stimulator
Description: Transcranial Magnetic Stimulation paired with Electrical Peripheral Nerve Stimulation
Study NCT04719273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT04719273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies